Stocktoria

Vericel Corp VCEL

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1997-02-04 · LEI

Vericel Corp financials (annual)

Revenue
$54.4M $63.9M $90.9M $117.8M $124.2M $156.2M $164.4M $197.5M $237.2M $276.3M 2016201720182019202020212022202320242025
Net income
-$19.6M -$17.3M -$8.1M -$9.7M $2.9M -$7.5M -$16.7M -$3.2M $10.4M $16.5M 2016201720182019202020212022202320242025
Free cash flow
-$21.3M -$14.7M -$3.1M -$9.8M $14.9M $21.1M $10.1M $15.3M -$5.8M $24.7M 2016201720182019202020212022202320242025

Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$276.3M$237.2M$197.5M$164.4M$156.2M$124.2M$117.8M$90.9M$63.9M$54.4M
Gross profit$205.6M$172.1M$135.6M$109.8M$106.0M$84.2M$80.3M$58.7M$33.6M$26.1M
R&D expense$27.6M$24.8M$21.0M$19.9M$16.3M$13.0M$30.4M$13.6M$12.9M$15.3M
SG&A expense$167.0M$142.8M$121.0M$106.9M$97.6M$68.8M$61.1M$49.0M$35.6M$27.4M
Operating income$11.0M$4.5M-$6.5M-$17.1M-$7.9M$2.4M-$11.3M-$3.9M-$15.0M-$19.2M
Interest expense$600,000$366,000$4,000$6,000$8,000$31,000$92,000$15,000
Income tax$859,000$148,000$814,000$721,000-$111,000$180,000$0$0$0$0
Net income$16.5M$10.4M-$3.2M-$16.7M-$7.5M$2.9M-$9.7M-$8.1M-$17.3M-$19.6M
EPS (diluted)$0.32$0.20$-0.07$-0.35$-0.16$0.06$-0.22$-0.20
Operating cash flow$51.9M$58.2M$35.3M$17.7M$29.0M$17.6M-$7.2M-$412,000-$13.2M-$19.9M
Free cash flow$24.7M-$5.8M$15.3M$10.1M$21.1M$14.9M-$9.8M-$3.1M-$14.7M-$21.3M
Cash & equivalents$100.1M$74.5M$69.1M$51.1M$68.3M$33.6M$26.9M$18.3M$26.9M
Inventory$17.6M$17.4M$13.1M$16.0M$13.4M$9.4M$6.8M$3.6M$3.8M$3.5M
Total assets$488.0M$432.7M$353.7M$273.0M$243.7M$205.6M$153.2M$118.7M$54.6M$48.6M
Total liabilities$133.3M$140.8M$127.7M$80.7M$73.2M$71.3M$42.1M$16.5M$32.0M$23.9M
Shareholders' equity$354.6M$292.0M$226.0M$192.3M$170.5M$134.3M$111.1M$102.2M$22.5M$24.7M

Growth · year-over-year · Revenue CAGR 19.8%

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue growth+16.5%+20.1%+20.2%+5.2%+25.8%+5.4%+29.7%+42.1%+17.5%+6.3%
Net income growth+59.4%-360.9%
EPS growth+60.0%-366.7%
Free cash flow growth-138.0%+51.6%-52.2%+41.3%

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.